Cinnarizine-induced parkinsonism in primates.
We describe the production of an experimental model of parkinsonism induced by cinnarizine (CNZ) in three healthy sylvanna monkeys. The drug produced a severe but reversible parkinsonism in all animals. After discontinuation of CNZ, all animals recovered but the oldest one was akinetic for 6 weeks. CNZ produced a persistent reduction in HVA and 5-HIAA levels in the CSF. Our data suggest a predominant presynaptic effect on DA and 5-HT neurons; and could account for the longstanding parkinsonism induced by calcium antagonist in some patients as well as the depression observed in these subjects.
García Ruiz
P J
PJ
Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain.
Mena
M A
MA
Peñafiel
N
N
De Yébenes
J G
JG
D000818:Animals; D015306:Biogenic Monoamines / Q000134:cerebrospinal fluid; D002936:Cinnarizine; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology; D000882:Haplorhini; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D009069:Movement Disorders / Q000209:etiology; D010302:Parkinson Disease, Secondary / Q000134:cerebrospinal fluid / Q000139:chemically induced*; D014202:Tremor / Q000139:chemically induced
D015306:Biogenic Monoamines; D002936:Cinnarizine; D006897:Hydroxyindoleacetic Acid; D004298:Dopamine; D006719:Homovanillic Acid